NASDAQ$GDRX
GoodRx Holdings Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
GoodRx's financial results for Q4 2022 were released, exceeding previously announced guidance.
GoodRx reported Q4 2022 total revenue of $184.1 million, exceeding guidance. Subscription revenue grew 42% year-over-year. Over 7 million Americans used GoodRx for their healthcare needs in the fourth quarter.
- Total revenue of $184.1 million, exceeding previously announced guidance.
- Net loss of $2.01 million; Net loss margin of 1.1%.
- Adjusted EBITDA of $49.6 million; Adjusted EBITDA Margin of 26.9%, exceeding previously announced guidance.
- Exited the quarter with over 7 million consumers of prescription-related offerings.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$184M
Revenue by segment
GoodRx · $179M total across 3 segments · Q4 2022
- Prescription Transactions$129M—72.3%
- Pharma Direct$24.9M—13.9%
- Subscription$24.6M—13.8%
Forward guidance
For the first quarter and full year 2023, management is anticipating total revenue of approximately $181 million to $183 million for Q1 and $780 million to $790 million for the full year. Adjusted EBITDA margin for the first quarter and full year 2023 is expected to be in the mid-twenty-percent range.
Tailwinds
- Focus on efficiently growing profitability
- Steady margin improvement
- Executing on strong cash conversion
- Balance sheet maintains a strong cash and liquidity position
- Aiding our capital allocation priorities to support our realigned organization in driving highly efficient and profitable growth
Headwinds
- Q1 2023 total revenue includes a $35 million to $45 million estimated impact to prescription transactions revenue related to the grocer issue.
- Uncertainty and potential variability of stock-based compensation expense
- Acquired intangible assets and related amortization
- Income taxes
- Targeted and strategic marketing investments over the course of the year, which are factored into our margin guidance for the first quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro